|Assessment Status||Rapid review complete|
|Indication||As monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.|
|Rapid review commissioned||20/12/2021|
|Rapid review completed||25/01/2022|
|Rapid review outcome||A full HTA is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that sotorasib not be considered for reimbursement*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.